Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbbVie

218.04
-10.1600-4.45%
Post-market: 217.80-0.2400-0.11%19:58 EDT
Volume:10.83M
Turnover:2.37B
Market Cap:385.18B
PE:103.82
High:223.87
Open:223.00
Low:216.00
Close:228.20
52wk High:244.81
52wk Low:163.81
Shares:1.77B
Float Shares:1.76B
Volume Ratio:2.63
T/O Rate:0.61%
Dividend:6.47
Dividend Rate:2.97%
EPS(TTM):2.10
EPS(LYR):2.40
ROE:112.85%
ROA:8.87%
PB:-2104.81
PE(LYR):91.01

Loading ...

AbbVie Inc. Stock Falls 4.5%, Underperforms Peers

Dow Jones
·
Yesterday

AbbVie price target raised to $261 from $255 at Morgan Stanley

TIPRANKS
·
Yesterday

Ironwood jumps after AbbVie reports Linzess sales beat

TIPRANKS
·
Yesterday

AbbVie Stock (ABBV) Wobbles as Humira Sales Take a Hit, Dims Q3 Glow

TIPRANKS
·
Yesterday

TD Cowen Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Yesterday

Citigroup Cuts AbbVie's Price Target to $235 From $240

MT Newswires Live
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Dominion Energy, Reddit, Brighthouse Financial

Reuters
·
Yesterday

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Benzinga
·
Oct 31

AbbVie’s Strong Financial Performance and Growth Potential Justifies Buy Rating

TIPRANKS
·
Oct 31

AbbVie expects strong company growth in 2026 despite Humira erosion

TIPRANKS
·
Oct 31

BUZZ-AbbVie falls as weak aesthetics segment sales overshadow Q3 results beat

Reuters
·
Oct 31

Stock Track | AbbVie Shares Plummet 5.11% Pre-Market Despite Raised Guidance as Q3 Earnings Show Mixed Results

Stock Track
·
Oct 31

AbbVie says Trump pressing for larger Medicare drug price cuts

Reuters
·
Oct 31

AbbVie see FY25 adjusted gross margin 84% of sales

TIPRANKS
·
Oct 31

AbbVie sees net leverage ratio 2x by end of 2026

TIPRANKS
·
Oct 31

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Oct 31

Abbvie Exec Says NOW Expect Total 2025 Skyrizi Global Sales of $17.3 Billion, Increase of $200 Million From Previous Forecast

THOMSON REUTERS
·
Oct 31

Abbvie Exec Says Step up in Humira Volume Erosion Expected This Year and Into 2026 to Be Partially Offset by Price Benefit - Conf Call

THOMSON REUTERS
·
Oct 31

Abbvie Exec Says Administration's Focus on Achieving Greater Reductions in 2027 Medicare Drug Price Negotiation Round Was Clear, but Outcomes Will Not Impact Long Term Outlook

THOMSON REUTERS
·
Oct 31

Abbvie Exec Says NOW Expect Total 2025 Net Revenues of Around $60.9 Billion, Increase of $400 Million From Prior Forecast

THOMSON REUTERS
·
Oct 31